Sanofi India Publishes Newspaper Notice for 70th AGM and Final Dividend

Sanofi India Limited has published newspaper notices regarding its 70th Annual General Meeting and final dividend arrangements, following the Board of Directors meeting held on March 25, 2026. The pharmaceutical company has fulfilled regulatory requirements by publishing the AGM notice in Business Standard (English) and Sakal (Marathi) newspapers on March 31, 2026.

Annual General Meeting and Dividend Details

The company has confirmed the scheduling of its 70th Annual General Meeting with comprehensive arrangements for shareholder participation:

Parameter:	Details
AGM Date:	Wednesday, April 29, 2026
Time:	3:30 PM (IST)
Mode:	Video Conferencing/Audio-Visual Means
Final Dividend:	Rs. 48.00 per equity share
Record Date:	Wednesday, April 22, 2026
Book Closure:	April 23-29, 2026 (both days inclusive)

The final dividend of Rs. 48.00 per equity share of Rs. 10.00 each for the Financial Year ended December 31, 2025, was previously recommended by the Board on February 25, 2026, and remains subject to member approval at the upcoming AGM.

New Independent Director Appointment

Based on the Nomination and Remuneration Committee's recommendation, the Board has approved the appointment of Mr. Siraj Azmat Chaudhry as Additional Director and Independent Director:

Appointment Details:	Information
Director Name:	Mr. Siraj Azmat Chaudhry
DIN:	00161853
Position:	Additional Director & Independent Director
Term Duration:	5 consecutive years
Term Period:	April 1, 2026 to March 31, 2031
Status:	Subject to AGM approval

Special Window for Share Transfers

SEBI has opened a special window for transfer and dematerialization of physical securities through Circular No. HO/38/13/11(2)/2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. This facility is available for securities sold/purchased before April 1, 2019:

Transfer Window Details:	Information
Window Period:	February 5, 2026 to February 4, 2027
Duration:	One year
Eligibility:	Previously rejected transfer requests
Reason for Rejection:	Document deficiency or process issues

Regulatory Compliance and Publication

The newspaper publication was made in compliance with SEBI regulations and MCA circulars regarding AGM conduct through video conferencing. The announcement includes comprehensive details about:

KYC registration requirements for shareholders
E-voting procedures for remote and AGM participation
Tax deduction at source on dividend payments
Bank account detail updates for dividend processing

Publication Details:	Information
Publication Date:	March 31, 2026
English Newspaper:	Business Standard
Regional Newspaper:	Sakal (Marathi)
Compliance Officer:	Haresh Vala
Website Availability:	www.sanofiindiatltd.com

The company has ensured all regulatory disclosures are made in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, maintaining transparency and stakeholder engagement throughout the process.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.69%	+6.21%	-5.44%	-26.20%	-44.07%	-57.16%

Sanofi India Limited has received a final income tax assessment order for FY 2022-23 with a determined tax liability of ₹12.37 crores, including interest. The pharmaceutical company disclosed this development to stock exchanges in compliance with regulatory requirements on March 28, 2026.

Assessment Order Details

The Assessment Unit of the Income Tax Department issued the final assessment order for FY 2022-23 (AY 2023-24), which was received by the company on March 27, 2026. The order determines a total tax liability of INR 12,36,99,710, including applicable interest charges.

Parameter	Details
Assessment Year	2023-24 (FY 2022-23)
Tax Liability	INR 12,36,99,710 (including interest)
Order Received Date	March 27, 2026
Issuing Authority	Assessment Unit, Income Tax Department

Key Issues Identified

The assessment order includes specific adjustments and disallowances that contributed to the determined tax liability. The Income Tax Department made adjustments on transfer pricing issues, which typically involve scrutiny of transactions between related entities to ensure they are conducted at arm's length prices.

Additionally, the order includes disallowance of payments made to healthcare professionals. Such payments in the pharmaceutical industry often relate to consulting fees, research collaborations, or educational activities, which may face regulatory scrutiny regarding their business justification and compliance with applicable guidelines.

Company's Response Strategy

Sanofi India has announced its intention to challenge the assessment order through the established legal framework. The company stated it would make an appeal before higher tax authorities against the adjustments and disallowances made in the assessment order.

Key Response Elements:

Filing appeal with higher tax authorities
Challenging transfer pricing adjustments
Contesting disallowance of healthcare professional payments
Seeking review of the determined tax liability

Regulatory Compliance

The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation requires listed companies to inform stock exchanges about material events that could impact their operations or financial position.

The communication was signed by Haresh Vala, Company Secretary and Compliance Officer, ensuring proper authorization and compliance with corporate governance requirements. The company has fulfilled its obligation to keep stakeholders informed about developments that may have financial implications for the organization.